Bad timing and Tulsi Tanti’s vaulting ambition nearly finished Suzlon a few years ago. And now he’s back with a new story.

The inability of analysts to fully understand biotech companies is keeping the value of Kiran Mazumdar-Shaw’s company down.

With the big players choosing the marketplace model, sellers are moving in to seize a piece of the action.

The Birla Matoshree gets the vote when it’s AGM time for Fortune India 500 companies.

Fulfilling social responsibilities ought to be a best practice, not lip service, for companies.

If the public sector giant doesn’t learn some new moves, it could find itself dwindling away.